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Abstract
Background: Assessing whether hepatitis C (HCV) co-infection with human immunodeficiency virus (HIV) is
associated with increased inflammation is complex. The liver, integral to inflammatory biomarker synthesis, is
compromised by HCV and alcohol abuse. Using single liver-synthesized biomarkers (e.g. C-reactive protein) to
represent inflammation may not be appropriate in HIV/HCV co-infection. We hypothesized that 1) detectable
HIV/HCV RNA was independently associated with increased inflammation; 2) a composite inflammation measure
describes inflammation differently from single inflammatory biomarkers.
Methods: We compared inflammation by HIV/HCV group in a cohort of 361 HIV infected participants from the
HIV-Longitudinal Interrelationships of Viruses and Ethanol study. Inflammatory biomarkers >75th percentile were
considered elevated. Associations between HIV/HCV group and elevated biomarkers were analyzed as a
composite measure (inflammatory burden) or individually. We defined inflammatory burden as number of
concurrently elevated biomarkers. Biomarkers included interleukin-6 (IL-6), C-reactive protein (CRP), cystatin C,
serum amyloid-A (SAA), tumor necrosis factor-alpha (TNF-α), interleukin-10 (IL-10). Covariates: alcohol, liver
fibrosis, comorbidities, CD4 count, antiretroviral therapy, substance use.
Results: Detectable HIV and HCV RNA (OR = 2.49; 95% CI = 1.05–5.89) and detectable HCV RNA alone (2.95; 1.08–8.01)
were independently associated with increased odds of having a greater inflammatory burden compared to
undetectable viremia. Elevated IL-10 (7.79; 1.90–31.97) and TNF-α (7.70; 1.42–41.83) were independently
associated with detectable HIV and HCV RNA. Elevated IL-10 was also associated with detectable HCV RNA
alone (5.51; 1.17, 25.84).
Conclusions: Detectable HIV and HCV replication versus undetectable replication was associated with
inflammatory burden and certain inflammatory biomarkers independently of alcohol consumption, liver
fibrosis and other comorbidities.
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Background
Several reports suggest that human immunodeficiency
virus (HIV) infection and hepatitis C (HCV) co-infection
with HIV are associated with increased cardiovascular
disease (CVD) risk [1-4]. Prior studies also link chronic in-
flammation, monocyte activation and/or altered coagula-
tion with acute myocardial infarction and death in HIV
infected people [5-8]. Whether HIV and HCV mediate
their effects on CVD risk through these mechanisms is not
known. Assessing whether HIV mono- and HIV/HCV co-
infection are associated with increased inflammation is
therefore important, though not straightforward. Liver
damage caused by alcohol consumption and HCV may
alter serum levels of inflammatory biomarkers that are
synthesized in the liver (e.g., C reactive protein) and pos-
sibly confound the association between viremia and bio-
markers of systemic inflammation. Moreover, using a
single biomarker, particularly one synthesized in the
liver, to represent systemic levels of inflammation may
not adequately represent this complex process. Whether
a composite measure involving multiple elevated inflam-
matory biomarkers, including those synthesized in the
liver, provides a more complete representation of the
state of inflammation in the setting of HIV/HCV infec-
tion is not clear.
The objective of this study, therefore, was to examine
the association between HIV and HCV viremia and bio-
markers of inflammation while accounting for alcohol
consumption and liver fibrosis.
Methods
Study sample
The HIV-Longitudinal Interrelationships of Viruses and
Ethanol (HIV-LIVE) study is a prospective cohort of 400
HIV infected people with current or past alcohol prob-
lems. For this analysis, 39 people were excluded because
they could not be defined in the HIV/HCV categor-
ies: 36 people were missing HIV RNA, 1 person was
missing HCV RNA, and 2 people were missing both.
Baseline data were collected for the remaining 361
HIV infected participants. As previously reported [9],
HIV-LIVE participants were enrolled from four different
sources from August 2001 to July 2003: (1) an existing
cohort of HIV-infected participants with alcohol problems;
(2) Boston Medical Center (BMC)’s Diagnostic Evaluation
Unit; (3) Beth Israel Deaconess Medical Center (BIDMC)
primary care and specialty clinics; and (4) local health care
sites or shelters in the Boston area. Participants were in-
cluded if they had a positive HIV antibody test (ELISA,
confirmed by Western blot), had two or more affirmative
responses to the CAGE (Cut down, Annoyed, Guilty, and
Eye opener) alcohol screening questionnaire [10] or
by physician-investigator diagnosis of alcoholism, spoke
English or Spanish, and had at least one contact person
likely to know the participant’s whereabouts. Individuals
were excluded if the 30-item Folstein Mini-Mental State
Examination score [11] was less than 21 or a trained inter-
viewer deemed the patient incapable of comprehending
the informed consent or answering interview questions.
Ethics statement
The Institutional Review Boards of Boston Medical Cen-
ter, Beth Israel Deaconess Medical Center, and the Uni-
versity of Pittsburgh approved this study.
Dependent variable
We defined an elevated biomarker as a serum biomarker
level >75th percentile for two main reasons. First there
are no thresholds associated with clinical events for
many of these biomarkers. Second, prior studies of in-
flammation in HIV infected populations have described
associations between biomarker quartiles and parame-
ters of HIV control as well as clinical endpoints such as
mortality [8,12].
We examined the following seven biomarkers:
interleukin-6 (IL-6), C-reactive protein (CRP), cystatin C,
serum amyloid A (SAA), tumor necrosis factor-alpha
(TNF-α), monocyte chemotactic protein-1 (MCP-1), and
interferon gamma (IFN-γ). The primary outcome, inflam-
matory burden score, was defined as the presence of zero,
one, two, or three or more elevated biomarkers. For ex-
ample, an inflammatory burden score of 0 corresponds
to having none of the seven biomarkers elevated. We
defined a score of 3 as having at least three of the seven
biomarkers elevated since few people had between four
and seven biomarkers elevated. Our secondary outcomes
were elevated individual inflammatory biomarkers and
included interleukin-10 (IL-10). Importantly, IL-10 was
not included in the inflammatory burden score because
of its anti-inflammatory properties. For both outcomes,
these biomarkers were chosen due to their associations
with cardiovascular morbidity and mortality [13-16],
HIV [8,17,18], and/or their synthesis in the liver [19,20].
IL-6 was measured by ELISA (Quantiglo Human IL-6
Immunoassay; R&D Systems, Minneapolis, MN) with an
assay range of 0.48–1500 pg/mL. The intra-assay and
inter-assay coefficients of variation (CVs) ranged from
3.0–5.8% and 6.3–9.6%, respectively. CRP, cystatin C
and SAA were measured using a particle enhanced im-
munonepholometric assay (BNII nephelometer; Dade
Behring Inc., Deerfield, IL). The CRP assay range was
0.16–1100 ug/mL. Intra-assay CVs ranged from 2.3–
4.4% and inter-assay CVs ranged from 2.1–5.7%. The
cystatin C assay range was 0.195–7.330 mg/L. Intra-
and inter-assay CVs were <5%. The SAA assay range
and minimum detectable level were determined by the
lower limit of the reference curve and were dependent
on the concentration of the SAA standard used in the
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assay (N SAA Standard SY). Intra-assay CVs ranged from
4.3–6.2% and inter-assay CVs ranged from 2.8–4.7%.
TNF-α, MCP-1, IL-10 and INF-γ were measured using
the Human Serum Adipokine Panel B LINCOplex Kit
(Linco Research, Inc. St. Charles, MO). The TNF-α and
MCP-1 assay ranges were 3.2–50,000 pg/mL. Intra- and
inter-assay CVs ranged from 1.4-7.9% and < 21%, respect-
ively. The IL-10 assay range was 3.2–10,000 pg/mL.
Intra- and inter-assay CVs ranged from 4.8–9.0% and
3.1–18.4%, respectively. For INF-γ, the assay range was
3.2–10,000 pg/mL. Intra- and inter-assay CVs ranged
from 4.8–9.0% and 3.1–18.4%, respectively. All assays
were performed at the Laboratory for Clinical Biochemis-
try Research (University of Vermont, Burlington, VT).
Independent variable
Detectable viremia was the independent variable catego-
rized into one of four groups: HIV and HCV RNA un-
detectable (undetectable), HIV RNA but not HCV RNA
detectable (HIV mono-detectable), HIV RNA undetect-
able but HCV RNA detectable (HCV mono-detectable),
and HIV and HCV RNA detectable (HIV/HCV detect-
able). The undetectable group was the referent group for
all analyses. HCV RNA was determined from serum
collected at the time of enrollment or from partici-
pants’ medical records. All participants were HIV anti-
body positive. HIV RNA testing was performed using a
branched-chain DNA assay or polymerase chain reac-
tion (PCR) [21]. The lower threshold of detection was
50–75 copies/mL. All subjects were tested for HCV in-
fection by measuring HCV antibodies and antibody-
positive subjects were tested for HCV RNA if these
data was unavailable from medical records. HCV RNA
was measured either by branched chain DNA or PCR-
based assays. The lower level of detection of the assays
was 615 IU/mL. HCV antibody-negative subjects were
assumed to be HCV RNA negative [22]. This HIV/
HCV categorization and the use of viremia (vs. ICD-9
code for example) enable comparisons by HIV and
HCV status simultaneously, while minimizing the po-
tential for misclassification bias.
Covariates
Demographic covariates were age; gender; race (white
vs. non-white). Liver fibrosis was assessed as a fibrosis
index-4 (FIB-4) score ≥1.45 [23]. We detailed alcohol use
data using the 30-day TimeLine Follow Back instrument
[24]. Current at-risk alcohol consumption was defined per
National Institute on Alcohol Abuse and Alcoholism cri-
teria: drinking >14 standard drinks for men (>seven for
women) per week or > four drinks on one occasion for
men (>three drinks for women) in the last 30 days [25].
Other covariates were CD4+ T-cell count <200 cells/mm3
and self-reported antiretroviral therapy (ART) use at time
of assessment, and obesity (body mass index (BMI)
≥30 kg/m2). Self-reported comorbid disease was defined as
a “yes” response to any of the following questions: “Has a
doctor ever told you that you had: CVD (peripheral vascu-
lar disease, hardening of the arteries in your neck or legs,
atherosclerosis; a stroke, cerebrovascular accident, blood
clot or bleeding in the brain, or transient ischemic attack;
or a heart attack or myocardial infarction); diabetes or high
blood sugar or sugar; hypertension or high blood pressure;
high cholesterol; renal disease (poor kidney function or
blood tests showing high creatinine); or anemia (low red
blood cell count, hemoglobin)?”
For other substance use variables, we defined current
smoking as a “yes” response to the question, “Do you cur-
rently smoke cigarettes every day or on some days?”; co-
caine use as self-reported use of “cocaine, crack or free
base”; and injection drug use as a “yes” response to the
question, “In your lifetime, have you ever injected drugs?”
Analysis
Baseline characteristics and biomarker distributions were
described and compared by HIV/HCV group using
ANOVA, Kruskal Wallis tests, or chi-square tests as
appropriate.
The primary analysis (labeled A) used a proportional
odds model to estimate the odds of more elevated (>75th
percentile) biomarkers. Two models were fit: (1) an un-
adjusted model with HIV/HCV status only; (2) an adjusted
model with HIV/HCV status, age, gender, FIB-4 score,
at-risk drinking, CD4 count, ART use, and self-reported
comorbidity. The proportional odds model estimates the
proportional odds (Podds) of having more than N con-
currently elevated biomarkers versus N or fewer. For ex-
ample, compared to those in the undetectable group, the
odds of having more than two versus two or fewer elevated
biomarkers is Podds greater for those in the HIV/HCV de-
tectable group. The assumption of proportional odds im-
plies that the coefficients that describe the relationship
between an inflammatory burden score of 0 compared to a
score of 1 or more are the same as those for an inflamma-
tory burden score of 1 compared to 2 or more. This as-
sumption was assessed by the Score Test. Our secondary
analyses used logistic regression to model the odds of hav-
ing an elevated individual biomarker (labeled B-I) adjusted
for the covariates in the models above. Spearman correl-
ation was used to assess potential collinearity in the re-
gression models. No pair of variables within a regression
model was highly correlated (r > 0.40). Analyses were con-
ducted using two-sided tests and a significance level of
0.05 and performed using SAS 9.3 (Cary, NC).
Results
Mean age (range: 40 – 46 years) was different (p < 0.01)
across the four HIV/HCV groups and study participants
Armah et al. BMC Infectious Diseases 2013, 13:399 Page 3 of 9
http://www.biomedcentral.com/1471-2334/13/399
were two-thirds non-white and three quarters male. Evi-
dence of liver fibrosis, diabetes, and CVD was highest
among those with HCV whereas at-risk alcohol con-
sumption and immunodeficiency were highest among
those with detectable HIV RNA (Table 1).
Participants in the undetectable group were least likely
to have concurrently elevated biomarkers (inflammatory
burden score = 2 or 3), while those in the HIV/HCV de-
tectable group were most likely (Figure 1). For individual
biomarkers, the prevalence of elevated IL-10, TNF-α,
cystatin C, and IL-6 was significantly different across the
four HIV/HCV groups (p < 0.05, Figure 1). The highest
proportions of elevated IL-10, TNF-α, and cystatin C oc-
curred in the HIV/HCV detectable group (Figure 1).
The HCV mono-detectable group had the highest pro-
portion of elevated IL-6 (Figure 1). The prevalence of el-
evated CRP, SAA, IFN-γ and MCP-1 was similar across
the four groups (p > 0.05, Figure 1).
Compared to participants with undetectable HIV and
HCV RNA, those in the HIV mono-detectable group
(proportional odds ratio (POR) = 1.89 (95% confidence
interval (CI) 1.03-3.46), HCV mono-detectable group
(POR = 2.70, 95% CI = 1.29-5.68), and HIV/HCV detectable
group (POR = 3.48, 95% CI = 1.87-6.46) had a significantly
higher inflammatory burden (Table 2). This association
persisted among participants in the HCV mono detect-
able and HIV/HCV detectable groups after adjusting for
potential confounders (Table 2). FIB4 score ≥1.45 was also
significantly associated with an increased burden of inflam-
matory biomarkers (p < 0.01, Table 2).
Compared to the undetectable group, the HIV/HCV
RNA detectable group had higher prevalence of elevated
IL-10, TNF-α, IL-6, and cystatin C. After adjustment for
potential confounders, this association remained signifi-
cant for IL-10 (OR = 7.79, 95% CI = 1.90-31.97) and
TNF-α (OR = 7.70, 95% CI = 1.42-41.83, Table 3). Eleva-
tions in CRP, SAA, IFN-γ, and MCP-1 were not signifi-
cantly different in any HIV/HCV group compared to the
undetectable group in either the unadjusted or adjusted
models (Table 3).
FIB-4 ≥1.45 was significantly associated with elevated
cystatin C (OR= 3.43, 95% CI = 1.45-8.10), IL-6 (OR = 3.22,
Table 1 Characteristics of 361 HIV-LIVE participants with HIV infection and alcohol problems stratified by detectable
HIV and HCV viremia
Subject characteristics HIV/HCV RNA both
undetectable (N = 59)
HIV RNA only
detectable (N = 122)
HCV RNA only
detectable (N = 53)
HIV/HCV RNA both
detectable (N = 127)
p-value
Age in years, mean (SD) 43 (7) 40 (8) 46 (7) 43 (7) <0.01
Female 16 (27.1) 26 (21.3) 11 (20.8) 35 (27.6) 0.59
Race, Non-White 42 (71.2) 84 (68.9) 34 (64.2) 84 (66.1) 0.84
FIB-4 ≥ 1.45 7 (16.3) 28 (28.2) 22 (59.4) 52 (54.7) <0.01
FIB-4, Median (Min, Max) 0.9 (0.5, 3.1) 1.1 (0.2, 7.5) 1.6 (0.7, 14.9) 1.6 (0.4, 17.1) 0.30
FIB-4, Mean (Standard Deviation) 1.1 (0.5) 1.3 (1.0) 2.8 (2.9) 2.3 (2.2)
Current at-risk alcohol consumption 15 (25.4) 46 (38.0) 9 (17.0) 43 (33.9) 0.03
Current CD4+ T-lymphocyte count
<200 cells/mm3
4 (6.8) 27 (22.9) 6 (11.8) 34 (26.8) <0.01
Current antiretroviral medication 52 (88.1) 56 (45.9) 50 (94.3) 65 (51.2) <0.01
BMI ≥30 kg/m2 13 (22.8) 23 (19.8) 8 (15.1) 25 (21.2) 0.76
Prevalent cardiovascular disease 3 (5.1) 2 (1.6) 6 (11.3) 15 (11.9) <0.01
Ever had diabetes 2 (3.4) 6 (4.9) 9 (17.0) 9 (7.1) 0.02
Ever had hypertension 16 (27.1) 28 (23.0) 14 (26.4) 33 (26.0) 0.91
Ever had high cholesterol 29 (49.2) 32 (26.2) 11 (20.8) 25 (19.7) <0.01
Ever had kidney disease 2 (3.4) 5 (4.1) 5 (9.4) 9 (7.1) 0.40
Ever anemic 17 (28.8) 28 (23.0) 12 (22.6) 31 (24.4) 0.84
Current smoker 39 (66.1) 93 (76.2) 40 (75.5) 102 (80.3) 0.22
Ever cocaine use 23 (39.0) 53 (43.4) 18 (34.0) 65 (51.2) 0.14
Ever injection drug use 10 (17.0) 26 (21.5) 46 (86.8) 115 (90.6) <0.01
Ever treated hepatitis C 0 (0) 3 (2.5) 8 (15.1) 6 (4.7) <0.01
All values are n (% of HIV/HCV group) unless otherwise specified.
HIV human immunodeficiency virus, HCV hepatitis C virus, FIB 4-liver fibrosis index-4, BMI body mass index.
The number of people with available FIB-4 measurements was 43 (HIV/HCV both undetectable), 99 (HIV only detectable), 37 (HCV only detectable),
95 (HIV/HCV both detectable).
Armah et al. BMC Infectious Diseases 2013, 13:399 Page 4 of 9
http://www.biomedcentral.com/1471-2334/13/399
95% CI = 1.44-7.20) [26] and MCP-1 (OR = 2.39, 95%
CI = 1.10- 5.20). Age above the median (42 years) was as-
sociated with lower odds of elevated IL-10, self-reported
high cholesterol and diabetes with higher odds of ele-
vated TNF-α, and current ART use with lower odds of
elevated TNF-α. Self-reported CVD and smoking were
associated with higher odds of elevated cystatin C, and
self-reported renal disease with higher odds of elevated
SAA and cystatin C. BMI ≥30 kg/m2 was associated with
higher odds of elevated CRP, and female gender with
lower odds of elevated MCP-1 (p < 0.05 for all; Additional
file 1: Table S1).
Discussion
This study suggests that HIV and HCV viremia contrib-
ute to elevations in inflammatory burden score, IL-10
and TNF-α, independently of and in addition to the con-
tribution from comorbid conditions. Our results also
suggest that a composite measure, comprising multiple
inflammatory biomarkers, may suggest an inflammatory
state is present even when individual biomarkers do not.
The fact that there was no significant association be-
tween any HIV/HCV group and CRP or SAA, two bio-
markers synthesized in the liver, suggests a need for
caution when using these biomarkers to assess inflam-
mation in this population with high potential for liver
morbidity.
This study differs from prior work [27-35] in that it at-
tempts to classify people as having more or less inflamma-
tion using a concomitantly elevated panel of inflammatory
biomarkers rather than emphasizing one individual bio-
marker of inflammation. Additionally, our results may be
more definitive than these prior studies because of our de-
tailed data on alcohol consumption and the inclusion of a
validated measure of liver fibrosis.
Findings from our study are consistent with those
from prior studies investigating the association between
HIV/HCV status and TNF-α [27-30], CRP [31,32], IL-10
[30,33], IFN-γ [30,34,36], IL-6 [28] and cystatin C [35].
However, some differences between our work and these
prior studies may reflect different biomarker outcome
categorization (quartiles versus detection, secretion, or
Figure 1 Inflammatory burden scores (number of elevated biomarkers) and individually elevated biomarkers by HIV/HCV group.
Elevated individual biomarkers were defined as a serum biomarker level >75th percentile. Inflammatory burden score, was defined as the
presence of zero, one, two, or three or more elevated biomarkers. For individual biomarkers, the prevalence of elevated IL-10, TNF-α, IL-6 and
cystatin C was significantly different across the four HIV/HCV groups (p < 0.05).
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means), HIV/HCV categorization (viremia versus anti-
body detection, in vitro stimulation with viral proteins)
sources of biomarkers (serum versus intrahepatic), ref-
erent groups (participants with undetectable HIV and
HCV viremia versus HIV or HCV mono-infected par-
ticipants) and adjustment covariates. The strong associ-
ations we reported between detectable viremia and the
anti-inflammatory cytokine, IL-10, are consistent with
prior research linking persistent viral infection with in-
creased IL-10 production [37]. The lack of data comparing
MCP-1, or SAA levels by HIV/HCV status suggests that
our findings for these particular cytokines may be novel.
The present study and other work have shown that
factors including viral replication, immunocompetence,
comorbidity [8,12,18,38], ART [8,18] and ART hepato-
toxicity [39], contribute to alterations in some inflamma-
tory biomarkers but not others. If the current study had
only investigated CRP, a clinically used inflammatory
biomarker [40], we may have concluded that detectable
HIV and HCV viremia were not associated with increased
inflammation. To more completely describe inflammation,
we propose that research into the inflammatory basis of
morbidity and mortality should also use composite mea-
sures of inflammatory biomarkers. These biomarkers often
reflect overlapping biological processes involved in the
immune response. Concurrently using multiple biomarkers
potentially reduces the variability (intra and inter-person)
inherent in measuring and analyzing individual biomarkers.
Using single biomarkers to quantify systemic inflammation
may be most appropriate in populations with minimal
inflammatory comorbid disease. However, a composite
measure of inflammation may be more appropriate in
HIV-infected populations, where multi-morbidity contrib-
utes strongly to chronic systemic inflammation. Future re-
search should compare the contributions of composite
versus individual inflammatory biomarker measures to
cardiovascular and other end-organ morbidity and mortal-
ity prediction.
Strengths of our study include a large, diverse panel of
inflammatory biomarkers. Our study sample had well
characterized measures of current or past alcohol prob-
lems, an important comorbid condition in HIV popula-
tions. We had a large proportion of non-white individuals
(>50%) enabling generalizability to important minority
populations. Limitations that warrant discussion include
the lack of HIV uninfected controls, the cross sectional na-
ture of the data presented, self-reported measures of health
conditions, and lack of direct cell surface immune activa-
tion data for comparison to serum cytokine data. The FIB-
4 index is a useful albeit imperfect measure of hepatic
fibrosis. This scale was employed as it provides clinically
useful prognostic information [23]. We do not expect the
Table 2 Association of HIV/HCV group with concurrently elevated (>75th percentile) inflammatory biomarkers
Model A (N = 218) Unadjusted Adjusteda
POR (95% CI) p-value POR (95% CI) p-value
Undetectable 1 – 1 –
HIV mono-detectable 1.89 (1.03, 3.46) 0.04 1.52 (0.68, 3.41) 0.31
HCV mono-detectable 2.70 (1.29, 5.68) <0.01 2.95 (1.08, 8.01) 0.03
HIV/HCV detectable 3.48 (1.87, 6.46) <0.01 2.49 (1.05, 5.89) 0.04
FIB-4≥ 1.45 – – 2.56 (1.39, 4.35) <0.01
High cholesterol – – 1.74 (0.97, 3.14) 0.06
Age greater than median (42 yrs) – – 0.61 (0.36, 1.04) 0.07
BMI≥ 30 kg/m2 – – 1.81 (0.93, 3.54) 0.08
Ever smoker – – 1.53 (0.85, 2.78) 0.16
CD4 > 200 cells/mm3 – – 0.63 (0.31, 1.26) 0.19
Renal disease – – 2.15 (0.67, 6.86) 0.20
Diabetes – – 1.90 (0.58, 6.21) 0.29
Current antiretroviral therapy use – – 0.74 (0.42, 1.31) 0.30
Prevalent cardiovascular disease – – 1.82 (0.56, 5.97) 0.32
Hypertension – – 0.78 (0.42, 1.45) 0.44
At-risk alcohol consumption – – 0.94 (0.55, 1.62) 0.83
Female – – 1.03 (0.55, 1.94) 0.93
aModel adjusted for age, gender, FIB-4 score, at-risk drinking, CD4 count, ART use, and self-reported comorbidity.
The ordinal logistic regression model estimates the proportional odds of having more than N concurrently elevated biomarkers versus N or fewer where N = 0, 1,
2, or 3 or more.
POR proportional odds ratio, HIV human immunodeficiency virus, HCV hepatitis C virus, FIB 4-liver fibrosis index-4, BMI body mass index, CD4-CD4+ T-lymphocyte count.
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index to perform differentially across the four HIV/HCV
groups being compared and thus believe that despite its
limitations, it is worthwhile to adjust for this covariate to
control for potential confounding in assessing the associ-
ation between HIV/HCV status and inflammatory bio-
markers. Sample size limitations may explain the strong
but non-significant associations of covariates like high
cholesterol, renal disease and smoking with inflammatory
burden. This limitation may also explain the stronger asso-
ciation of the HCV mono-detectable group with inflamma-
tory burden versus the HIV/HCV detectable group. As
with all observational studies, we cannot exclude the po-
tential for residual confounding.
Conclusion
In a cohort of HIV infected people with current or past
alcohol problems, detectable HIV and HCV RNA com-
pared to undetectable viremia was associated with greater
systemic inflammation as measured by an inflammatory
burden score and elevations in certain inflammatory bio-
markers. This association was independent of at-risk drink-
ing, liver fibrosis and other comorbidities.
Table 3 Association of HIV/HCV group with individually elevated (>75th percentile) biomarkers
Biomarker elevated HIV/HCV group Unadjusted OR (95% CI) Adjusted ORa (95% CI)
Model B (N = 218) Undetectable 1 1
Interleukin-10 HIV mono-detectable 4.74* (1.36, 16.48) 2.95 (0.74, 11.85)
HCV mono-detectable 5.39* (1.39, 20.84) 5.51* (1.17, 25.84)
HIV/HCV detectable 9.22* (2.69, 31.55) 7.79* (1.90, 31.97)
Model C (N = 218) Undetectable 1 1
Tumor necrosis factor-α HIV mono-detectable 4.50* (1.29, 15.70) 4.44 (0.86, 22.82)
HCV mono-detectable 4.15* (1.04, 16.47) 4.45 (0.68, 29.02)
HIV/HCV detectable 8.50* (2.48, 29.16) 7.70* (1.42, 41.83)
Model D (N = 196) Undetectable 1 1
Interleukin-6 HIV mono-detectable 1.33 (0.49, 3.66) 0.57 (0.15, 2.16)
HCV mono-detectable 5.17* (1.79, 14.94) 2.99 (0.75, 11.98)
HIV/HCV detectable 3.33* (1.28, 8.70) 1.47 (0.40, 5.35)
Model E (N = 218) Undetectable 1 1
Cystatin-C HIV mono-detectable 1.50 (0.56, 4.01) 0.49 (0.12, 2.02)
HCV mono-detectable 2.22 (0.73, 6.73) 0.40 (0.07, 2.34)
HIV/HCV detectable 5.04* (1.98, 12.85) 1.60 (0.39, 6.57)
Model F (N = 218) Undetectable 1 1
C-reactive protein HIV mono-detectable 1.16 (0.54, 2.51) 0.99 (0.35, 2.84)
HCV mono-detectable 1.09 (0.42, 2.80) 1.41 (0.41, 4.90)
HIV/HCV detectable 0.86 (0.39, 1.90) 0.69 (0.22, 2.14)
Model G (N = 210) Undetectable 1 1
Serum amyloid A HIV mono-detectable 0.81 (0.36, 1.80) 0.58 (0.19, 1.79)
HCV mono-detectable 0.69 (0.25, 1.89) 0.38 (0.09, 1.66)
HIV/HCV detectable 1.01 (0.46, 2.22) 0.72 (0.22, 2.31)
Model H (N = 218) Undetectable 1 1
Interferon-γ HIV mono-detectable 1.40 (0.52, 3.78) 1.65 (0.46, 5.87)
HCV mono-detectable 1.68 (0.53, 5.28) 2.63 (0.59, 11.76)
HIV/HCV detectable 0.92 (0.32, 2.60) 1.03 (0.25, 4.30)
Model I (N = 218) Undetectable 1 1
Monocyte chemoattractant protein-1 HIV mono-detectable 1.67 (0.72, 3.84) 2.96 (0.80, 10.95)
HCV mono-detectable 1.38 (0.50, 3.79) 3.71 (0.83, 16.53)
HIV/HCV detectable 1.37 (0.59, 3.21) 3.48 (0.88, 13.69)
aModels adjusted for age, gender, FIB-4 score, at-risk drinking, CD4 count, ART use, and self-reported comorbidity. See Additional file 1: Table S1 for odds ratios
for covariates.
*p-value < 0.05.
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Additional file 1: Table S1. Association of HIV/HCV group and
covariates with individually elevated (>75th percentile) biomarkers.
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